Portola Pharmaceuticals Inc., of South San Francisco, appointed Mardi Dier chief financial officer.

Prestwick Pharmaceuticals Inc., of Washington, appointed George Horner president and CEO.

Protagen AG, of Dortmund, Germany, appointed Michael Motschmann and Gerhard Steinkamp to its board.

Samaritan Pharmaceuticals Inc., of Las Vegas, promoted Kristi Eads vice president of business development.

Sapphire Therapeutics Inc., of Bridgewater, N.J., appointed Herbert Conrad president and CEO, Bruce Peacock to its board and William Mann to vice president, corporate development.

Seaside Therapeutics, of Cambridge, Mass., appointed Steven Hyman and Geoffrey Duyk founding members of its board, and Timothy Ocain senior vice president of research and development.

Sequenom Inc., of San Diego, appointed Paul Hawran to its board, and Michael Monko senior vice president of sales and marketing.

Solexa Inc., of Hayward, Calif., appointed Blaine Bowman and Roy Whitfield to its board.

Surface Logix Inc., of Boston, appointed James O'Shea to its board.

Synovics Pharmaceuticals Inc., of Phoenix, appointed Steven Getraer CEO of its wholly owned subsidiary, Kirk Pharmaceuticals.

Synthetech Inc., of Albany, Ore., appointed Gregory Hahn president and chief operating officer.

Targanta Therapeutics, of Indianapolis, appointed Gayle Crick Fischer vice president, marketing; Roger Miller vice president, operations and manufacturing; William Vladuchick vice president, strategic development; and Margaret Wasilewski vice president, clinical development and medical science team leader.

TcLand SA, of Nantes, France, appointed Alain Huriez chairman and CEO, and Elisabeth Hubert and Marc de Garidel to its board.

U.S. BioDefense Inc., of City of Industry, Calif., appointed Charles Wright executive vice president.

Xenomics Inc., of New York, appointed David Sidransky to its board.

No Comments